@StephanieKelton , was just exposed to your theory and I’m captivated. Just bought your book. Curious how not having US as a reserve currency impacts your theory? Is bitcoin a solution, or not? Thank for pioneering new ideas.
Check out this podcast episode I was a guest on with @MercyOne_Iowa to learn about circulating tumor DNA and how @NateraGenetics is utilizing ctDNA to improve the management of cancer patient care through our molecular residual disease assay, Signatera!! https://t.co/Z8ylzjmtm8
For Jeffrey, who is living with metastatic #melanoma, @NateraGenetics's Signatera test helped him and his oncologist monitor immunotherapy treatment.
Click the link to watch his story to learn more about his experience 👉 https://t.co/llRtiJXRez
#SkinCancerAwarenessMonth
With CT contrast scans being actively restricted in many hospital systems, please contact me to learn more about how #ctdna Signatera can help as a surveillance tool!
Latest findings from CIRCULATE-Japan shared at ASCO #GI22. More than 3,000 #ColorectalCancer patients are enrolled in this study, which is the largest prospective, multi-center, MRD-guided trial in CRC, using Signatera to monitor #MRD status. https://t.co/ynnyEkTQD9
Though ASCO GI may be over, the excitement is still here!
Read about new data presented that shows Signatera's ability to predict #colorectalcancer relapse 8 months before radiological detection of recurrence: https://t.co/chfFzHEKLN
#GI21#CRCSM@CBankheadMPT@TennaVesterman
Big news! Draft LCD from #Medicare was issued to use #Signatera for #immunotherapy response monitoring in solid tumors. We're thrilled to be able to serve this broad set of patients who may benefit from MRD testing. https://t.co/r0HphgOMzd
🆕 Signatera is now covered by Medicare in stages II-III #colorectalcancer! Huge win for cancer patients and providers - expanding access to this new technology will help guide cancer care.
Read our press release here: https://t.co/TFgKNBCzlv
#ctDNA#SignateraLooksDeeper
Excited to announce the finalization of CMS coverage for MRD testing for the millions of early stage CRC patients. This marks a new era in the personalization of management of early stage colorectal cancer. #ctDNA#MRD#Signatera
https://t.co/uHXiliQsQ0